ABSTRACT To investigate whether the effects of nifedipine on methacholine induced bronchoconstriction could impair pulmonary gas exchange in bronchial asthma a randomised, double blind, crossover study in 13 symptom free asthmatic subjects was designed. Each patient underwent a methacholine bronchial challenge test on two separate days one week apart, after having either oral nifedipine (20 mg thrice daily) or placebo for three days. Arterial blood gases were measured before and after methacholine challenge in nine subjects. Prechallenge values of forced expiratory volume in one second (FEV1) and arterial oxygen tension (Pao2) were similar after nifedipine and after placebo. After challenge, the cumulative doses of methacholine required to produce a 20% fall in FEV, (PD20 FEV1) were significantly larger after nifedipine (280 (SD 347)) cumulative breath units (CBU) than after placebo (120 (183) CBU; p < 0.01). After challenge the fall in Pao2 values (17.1 (1.6) mm Hg; (2.28 (0.21) kPa)) was significantly greater than after placebo (11.7 (2.4) mm Hg; (1.56 (0.32) kPa) p < 0.03). Our data show that although oral nifedipine significantly reduces airway reactivity in patients with mild bronchial asthma, it also adversely affects pulmonary gas exchange, resulting in a lowered postchallenge Pao2, probably because of worsening ventilation-perfusion relationships.
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There is increasing interest in the effects of calcium channel blocking agents on airway smooth muscle contraction. 1 Society."4 The necessary concentrations of methacholine were prepared from a stock solution containing 25 mg/ml, (the diluents being 0.5% NaCl, 0.275% NaHCO3, and 80% propylene glycol in water). The stock solution was renewed every two months and stored at 4°C until solutions were prepared.'5 16 The same solution was used in the two challenges carried out in each subject. The concentrations of methacholine used successively were: 0.1, 0.5, 1, 2, 5, 10, 25 mg/ml, and the last concentration was repeated until the cumulative dose causing a 20% fall in FEV, (PD2o FEV1) was reached. Methacholine was delivered by intermittent inhalation of aerosol in five nondosimeter regulated breaths via a handgrip nebuliser (DeVilbiss No 42, DeVilbiss Co, Somerset, Pennsylvania, USA), and it was administered by the same observer for all patients. Subjects were instructed to take five breaths of each methacholine concentration, beginning close to functional residual capacity and inhaling slowly to total lung capacity in a constant manner. After baseline spirometric measurements had been obtained, increasing concentrations of methacholine chloride from 0.1 to 25mg/ml were inhaled. Each series of five inhalations was followed after three minutes by spirometric measurements, and all were obtained within six minutes of the last inhalation.
Measurements of arterial blood gas tensions and pH (Radiometer BMS3 MK2, Copenhagen) were made immediately before challenge and were repeated within four to six minutes of achieving a 20% fall in FEVY. In four patients blood gas tensions could not be obtained.
The results of methacholine challenge were analysed by constructing a dose-response curve on semilogarithmic paper. Doses were expressed as cumulative breath units (CBU). The cumulative dose at which FEV, had deteriorated by 20% of control values was considered the provocation dose (PD20 FEV1 Effect of nifedipine on arterial hypoxaemia occurring after methacholine challenge in asthma exchange in patients with asthma. Our study showed that baseline prechallenge values of Pao2 were similar after nifedipine and placebo, even though a lower Pao2 might have been expected after nifedipine as a result of impairment in VA/0 mismatching. There is, however, evidence that the systemic vasodilation that occurs with nifedipine, 24 26 by increasing cardiac output, results in a raised mixed venous oxygen tension (PVo2) and in this way may offset the expected fall in arterial Po2.
The greater reduction in postchallenge Pao2 after nifedipine than after placebo is probably related to further impairment in VA/4 abnormalities. Whether inhibition of hypoxic pulmonary vasoconstriction may explain part of the reduced Pao2 remains to be elucidated. Presumably any simultaneous increase in cardiac output was insufficient to compensate for the altered efficiency of pulmonary gas exchange provoked by methacholine challenge. There were no significant differences in postchallenge FEV1 values after nifedipine and after placebo. Neither were there any significant correlations between the changes in Pao2 and PA-ao2 that followed methacholine challenge and the doses of methacholine. This finding is particularly important as it suggests that the higher methacholine concentrations used after nifedipine cannot be implicated in the lower Pao2 values achieved. The data therefore suggest that nifedipine exacerbates hypoxaemia in patients with mild bronchial asthma when they are submitted to methacholine challenge.
It is self-evident that worsening of hypoxaemia associated with nifedipine is potentially an important side effect in patients with reversible airways obstruction who develop acute bronchoconstriction. In patients with associated cardiovascular diseases, such as angina pectoris, such an effect might be particularly serious. Our conclusions therefore appear clearly at variance with those of a recent report,27 in which the safety of nifedipine was assessed only on spirometric grounds in patients with asthma, chronic obstructive lung disease, and coronary artery disease. In that study no adverse effects were observed in lung function tests but Pao2 was not measured. A decrease in Pao2 within the range observed in our study in a patient without underlying hypoxaemia is unlikely to be clinically important. A similar reduction of Pao2 in a patient with pre-existing hypoxaemia, however, could be hazardous, although we do not know whether methacholine induced bronchoconstriction represents a perfect model of spontaneous exacerbations of asthma.
